Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

NCT02607774 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: Midazolam
DRUG: AIN457

Sponsor

Novartis Pharmaceuticals